Flen Health's Novel Gel Gets FDA Nod, Aims to Combat Diabetic Ulcers

KONTICH, Belgium – May 12, 2026 – A promising new weapon in the fight against one of diabetes' most devastating complications has cleared a critical regulatory hurdle in the United States. Flen Health Pharma NV, a Belgian biopharmaceutical company, announced it has received positive feedback from the U.S. Food and Drug Administration (FDA) for its novel biologic, VES gel, a treatment designed to heal chronic diabetic foot ulcers (DFUs).

The feedback, which followed an INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs (INTERACT) meeting, provides Flen Health with a clear development pathway toward human clinical trials. This milestone marks a significant step forward for a potential therapy aimed at a condition that affects millions and is a leading cause of lower-limb amputations.

The Scope of a Silent Epidemic

For millions of people living with diabetes, foot ulcers are a constant and terrifying threat. These open sores, which can result from minor scrapes or pressure on the feet, are notoriously difficult to heal due to the underlying disease's impact on circulation and nerve function. According to medical statistics, up to a quarter of all diabetic patients will develop a foot ulcer in their lifetime.

The consequences are often severe. DFUs are the primary gateway to infection and, ultimately, amputation, accounting for approximately 85% of all diabetes-related lower-extremity amputations. The economic toll is equally staggering, costing the U.S. healthcare system an estimated $13 billion annually in direct treatment costs. The healing process is frequently challenged by a hostile wound environment characterized by impaired inflammatory responses, disrupted cellular communication, and persistent bacterial colonization.

Even when an ulcer does heal, the victory can be short-lived. Recurrence rates are alarmingly high, with some studies showing that over 60% of patients experience another ulcer within five years. This cycle of ulceration, infection, and potential amputation creates a significant burden on patients, their families, and the healthcare system, highlighting a profound unmet need for more effective treatments that can accelerate and sustain wound closure.

A Novel Approach to Healing

Flen Health aims to address this gap with VES gel, which it describes as a first-in-class, patented topical biologic. Unlike simple dressings that maintain a moist environment or debriding agents that clear away dead tissue, VES gel is designed to be an active participant in the healing process. Its unique formulation combines a proprietary recombinant enzyme complex within an alginate ointment.

This dual-pronged approach leverages biotechnology to fundamentally alter the wound's biology. The company states the gel works to modulate inflammation—a key process that is often dysregulated in chronic wounds—and actively promote healing. Furthermore, it is designed to eliminate bacteria and yeast, which frequently contaminate DFUs and impede recovery, without contributing to the growing problem of antibiotic resistance. The alginate base itself serves as an effective vehicle, delivering the biologic agent directly to the wound bed while helping to manage wound exudate.

Because it integrates a biologic agent with a medical device component (the ointment), VES gel is being reviewed as a combination product, a category that often involves a more complex regulatory path. The goal is to create a therapy that is not only more effective but also easy for clinicians and patients to apply topically.

Navigating the FDA Gauntlet

The recent feedback from the FDA is a pivotal de-risking event for Flen Health's U.S. ambitions. The INTERACT meeting is a mechanism designed by the FDA for sponsors of innovative and complex products to gain early, informal agency advice before committing to expensive, large-scale studies. It allows regulators to weigh in on a company's proposed plans for Chemistry, Manufacturing, and Controls (CMC) as well as the design of nonclinical toxicology studies.

Receiving positive written feedback indicates that the FDA is, in principle, aligned with Flen Health's strategy for manufacturing VES gel and for conducting the necessary safety studies required before it can be tested in humans. This provides the company with what its U.S. Business Strategy Director, Julie Kerckhof, called a “clear regulatory roadmap to advance VES gel toward clinical trials in the United States.”

This early guidance is invaluable. It helps prevent costly missteps and ensures that the data generated in preclinical development will meet the FDA's stringent requirements for an Investigational New Drug (IND) application, the formal request to begin clinical trials. While this is not an approval, it is a crucial vote of confidence in the company's scientific approach and significantly smooths the path forward.

A Belgian Firm's American Ambition

With over 25 years of experience developing and marketing wound and skin healing solutions across Europe and in more than 40 countries, Flen Health is no newcomer to the field. This move represents a calculated and strategic expansion into the world's largest and most lucrative pharmaceutical market. The positive FDA feedback serves as a key asset as the company now embarks on its next critical phase: finding a partner.

Flen Health has been transparent about its search for a strategic partner to support the clinical development and eventual U.S. commercialization of VES gel. This is a common and often essential strategy for international companies entering the complex U.S. market. A partnership with an established pharmaceutical or biotech firm could provide not only financial resources for costly late-stage trials but also invaluable infrastructure, including an experienced sales force, established relationships with hospitals and clinics, and expertise in navigating U.S. reimbursement systems.

With plans to initiate U.S. clinical trials in 2026, the company is now focused on completing its IND-enabling studies and solidifying a partnership. The success of VES gel could represent a significant new revenue stream and establish Flen Health as a key player in the advanced wound care market in North America, all while potentially changing the standard of care for millions of diabetic patients at risk of amputation.